Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hydrocodone Bitartrate,Paracetamol
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Acura Pharmaceuticals Provides Development Update on LTX-03
Details : In clinical study, formulations of LTX-03 demonstrated, under fasted conditions, analgesic levels of hydrocodone in the blood when taken at a recommended one or two tablet dose but reduced the maximum blood level up to 34% when exposed to higher buffer i...
Product Name : LTX-03
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2022
Lead Product(s) : Hydrocodone Bitartrate,Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydrocodone Bitartrate,Paracetamol
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Abuse Deterrent Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03
Details : LIMITx™ LTX-03, works by neutralizing stomach acid with buffering ingredients as increasing numbers of tablets are swallowed thereby reducing the stomach acid available to cause the release and systemic absorption of active from micro-particles contain...
Product Name : LTX-03
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 03, 2022
Lead Product(s) : Hydrocodone Bitartrate,Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Abuse Deterrent Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Hydrocodone Bitartrate,Paracetamol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Abuse Deterrent Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03
Details : LTX-03 is an immediate-release hydrocodone bitartrate with acetaminophen tablet. The agreement aims at extending the FDA Acceptance Date for LTX-03 to February 28, 2022.
Product Name : LTX-03
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 26, 2021
Lead Product(s) : Hydrocodone Bitartrate,Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Abuse Deterrent Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Hydrocodone Bitartrate,Paracetamol
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Acura Pharmaceuticals Provides Development Update on LTX-03
Details : LTX-03 (hydrocodone with acetaminophen) demonstrated, under fasted conditions, analgesic levels of hydrocodone in the blood when taken at a recommended one or two tablet dose.
Product Name : LTX-03
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2021
Lead Product(s) : Hydrocodone Bitartrate,Paracetamol
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydrocodone Bitartrate,Paracetamol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Acura Pharmaceuticals Provides an Update on the Development of LTX-03
Details : In conjunction with a third party formulation developer, the formulation and manufacturing process for LTX-03 has been optimized for commercial scale.
Product Name : LTX-03
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 01, 2020
Lead Product(s) : Hydrocodone Bitartrate,Paracetamol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable